Absolute Quantification of Aβ1-42 in CSF Using a Mass Spectrometric Reference Measurement Procedure

Area of Science:

• Neuroscience
• Biochemistry
• Analytical Chemistry

Background:

• Alzheimer's disease (AD) is a leading cause of dementia in the elderly.
• Current AD diagnosis relies on cognitive tests, with cerebrospinal fluid (CSF) amyloid-beta (Aβ) peptide levels gaining importance.
• Existing antibody-based assays like ELISA for Aβ quantification suffer from variability, limiting clinical utility.

Purpose of the Study:

• To develop an antibody-independent Reference Measurement Procedure (RMP) for accurate Aβ quantification in CSF.
• To overcome the limitations of inter- and intra-laboratory variability associated with current diagnostic methods.
• To establish a reliable method for measuring CSF Aβ1-42 within a clinically relevant range.

Main Methods:

• Development of an RMP utilizing solid-phase extraction (SPE) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).
• Employment of stable, isotope-labeled Aβ peptides as internal standards for absolute quantification.
• Utilization of a high-resolution quadrupole-orbitrap hybrid instrument for precise mass spectrometry measurements.

Main Results:

• The developed RMP enables antibody-independent quantification of CSF Aβ.
• The method demonstrates reliable measurement of Aβ1-42 in the range of 150-4,000 pg/mL.
• This approach addresses the variability issues inherent in antibody-based biomarker assays.

Conclusions:

• A novel LC-MS/MS based RMP provides accurate and reproducible quantification of CSF Aβ1-42.
• This antibody-independent method offers a more robust approach for AD biomarker analysis.
• The established RMP has the potential to enhance diagnostic accuracy and clinical trial reliability for Alzheimer's disease.